MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
RVMD stock logo

RVMD

Revolution Medicines, Inc.

$149.55
1.06
 (0.71%)
Exchange:  NASDAQ
Market Cap:  31.794B
Shares Outstanding:  36.473M
Delayed data
Calculate RVMD Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Mark A. Goldsmith
Full Time Employees:  616
Address: 
700 Saginaw Drive
Redwood City
CA
94063
US
Website:  https://www.revmed.com
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company’s portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/06 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue11,58000
Gross Profit11,5800-16,558
EBITDA-477,876-677,700-1,090,512
Operating Income-487,185-689,524-1,182,369
Net Income-436,367-600,093-1,131,301

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,088,5912,558,3012,354,508
Total Liabilities262,397293,097723,211
Total Stockholders Equity1,826,1942,265,2041,631,297
Total Debt87,944135,843158,702
Cash and Cash Equivalents696,148543,064383,745

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-350,572-557,436-897,741
Capital Expenditure-7,729-10,308-15,990
Free Cash Flow-358,301-567,744-913,731
Net Income-436,367-600,093-1,131,301
Net Change in Cash534,736-153,084-158,159

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)1,472,585.584Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)14,226,407.719Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)5,551,603.054Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-2,845,281.543Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-294,517.116Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-1,110,320.610Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)83,124.466Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)5,620,712.157Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)1,854,194.657Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)3,155,315.860Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)30,482,988.834Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)11,895,445.234Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)9.750Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)29.560Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.440Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)7Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)6Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
-600093000  ?P/E
 (TTM)
: 
-21.55
?Enterprise Value
 (TTM)
: 
31.441B  ?EV/FCF
 (TTM)
: 
-29.34
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.83  ?ROIC
 (TTM)
: 
-0.7
?Net Debt
 (TTM)
: 
-2153456000  ?Debt/Equity
 (TTM)
: 
0.1
?P/B
 (TTM)
: 
19.71  ?Current Ratio
 (TTM)
: 
6.8

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about RVMD valuation

Is Revolution Medicines, Inc. (RVMD) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Revolution Medicines, Inc. (RVMD) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is RVMD a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether RVMD trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is RVMD’s P/E ratio?

You can see RVMD’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for RVMD?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is RVMD a good long-term investment?

Whether RVMD fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

RVMD

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.71
MARKETSnap

Trading Metrics:

Open: 150.23   Previous Close: 148.49
Day Low: 146.5   Day High: 151.09
Year Low: 34   Year High: 166.5
Price Avg 50: 137.18   Price Avg 200: 90.51
Volume: 2.765M   Average Volume: 3.036M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
05-06-2026 02:45
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
01-06-2026 10:16
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case
01-06-2026 09:26
Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
14-05-2026 06:04
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
07-05-2026 13:50
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
06-05-2026 18:00
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read